CTI BioPharma Corp. Company Profile (NASDAQ:CTIC)

About CTI BioPharma Corp. (NASDAQ:CTIC)

CTI BioPharma Corp. logoCTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTIC
  • CUSIP: N/A
  • Web: www.ctibiopharma.com
Capitalization:
  • Market Cap: $104.69 million
  • Outstanding Shares: 31,725,000
Average Prices:
  • 50 Day Moving Avg: $3.40
  • 200 Day Moving Avg: $3.92
  • 52 Week Range: $2.70 - $6.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.38
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $36.55 million
  • Price / Sales: 2.86
  • Book Value: $1.37 per share
  • Price / Book: 2.41
Profitability:
  • EBIDTA: ($50,380,000.00)
  • Net Margins: -136.76%
  • Return on Equity: -418.99%
  • Return on Assets: -73.69%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 2.15%
  • Quick Ratio: 2.11%
Misc:
  • Average Volume: 122,542 shs.
  • Beta: 0.83
  • Short Ratio: 4.23
 

Frequently Asked Questions for CTI BioPharma Corp. (NASDAQ:CTIC)

What is CTI BioPharma Corp.'s stock symbol?

CTI BioPharma Corp. trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma Corp.'s stock split? How did CTI BioPharma Corp.'s stock split work?

CTI BioPharma Corp.'s stock reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma Corp. stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma Corp.'s earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.63. The firm earned $22.23 million during the quarter. CTI BioPharma Corp. had a negative net margin of 136.76% and a negative return on equity of 418.99%. View CTI BioPharma Corp.'s Earnings History.

When will CTI BioPharma Corp. make its next earnings announcement?

CTI BioPharma Corp. is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for CTI BioPharma Corp..

Where is CTI BioPharma Corp.'s stock going? Where will CTI BioPharma Corp.'s stock price be in 2017?

1 equities research analysts have issued twelve-month price objectives for CTI BioPharma Corp.'s stock. Their forecasts range from $7.50 to $7.50. On average, they anticipate CTI BioPharma Corp.'s stock price to reach $7.50 in the next twelve months. View Analyst Ratings for CTI BioPharma Corp..

Who are some of CTI BioPharma Corp.'s key competitors?

Who are CTI BioPharma Corp.'s key executives?

CTI BioPharma Corp.'s management team includes the folowing people:

  • Richard L. Love, Interim Chairman of the Board
  • Adam R. Craig M.D., Ph.D., President, Chief Executive Officer, Director
  • Bruce J. Seeley, Principal Financial Officer, Executive Vice President, Chief Commercial and Administrative Officer, Secretary
  • Jack W. Singer M.D., Interim Chief Medical Officer, Global Head of Translational Medicine, Executive Vice President, Chief Scientific Officer
  • Matthew J. Plunkett Ph.D., Executive Vice President, Corporate Development
  • Nancy L. Boman Ph.D., Senior Vice President of Clinical Development and Regulatory Affairs
  • Monique M. Greer, Senior Vice President of Corporate Communications and Investor Relations
  • Michael A. Metzger, Director
  • Matthew Perry, Director
  • Laurent Fischer M.D., Independent Director

Who owns CTI BioPharma Corp. stock?

CTI BioPharma Corp.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (19.99%), STONEPINE CAPITAL MANAGEMENT, LLC (7.60%), Stonepine Capital Management LLC (7.20%), Vanguard Group Inc. (2.69%), Blair William & Co. IL (0.18%) and Northern Trust Corp (0.14%). Company insiders that own CTI BioPharma Corp. stock include Jack W Singer, James A Bianco, Louis A Bianco, Matthew Plunkett, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma Corp..

Who sold CTI BioPharma Corp. stock? Who is selling CTI BioPharma Corp. stock?

CTI BioPharma Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for CTI BioPharma Corp..

Who bought CTI BioPharma Corp. stock? Who is buying CTI BioPharma Corp. stock?

CTI BioPharma Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and WASHINGTON TRUST Co. View Insider Buying and Selling for CTI BioPharma Corp..

How do I buy CTI BioPharma Corp. stock?

Shares of CTI BioPharma Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma Corp.'s stock price today?

One share of CTI BioPharma Corp. stock can currently be purchased for approximately $3.30.


MarketBeat Community Rating for CTI BioPharma Corp. (NASDAQ CTIC)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CTI BioPharma Corp. (NASDAQ:CTIC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.50 (127.27% upside)

Analysts' Ratings History for CTI BioPharma Corp. (NASDAQ:CTIC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/29/2016Piper Jaffray CompaniesReiterated RatingNeutral$7.50N/AView Rating Details
2/10/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
2/10/2016WallachBeth CapitalDowngradeHold -> SellN/AView Rating Details
2/8/2016S&P Equity ResearchLower Price Target$4.80 -> $3.90N/AView Rating Details
(Data available from 8/22/2015 forward)

Earnings

Earnings History for CTI BioPharma Corp. (NASDAQ:CTIC)
Earnings by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)
Earnings History by Quarter for CTI BioPharma Corp. (NASDAQ CTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017        
8/3/2017Q2 2017($0.60)$0.03$22.23 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.70)($0.71)$0.75 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.70)($0.23)$9.14 millionViewListenView Earnings Details
8/4/2016Q2($0.10)($0.07)$7.36 millionViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01$36.48 millionViewN/AView Earnings Details
2/16/2016Q4($0.18)($0.13)$11.32 millionViewN/AView Earnings Details
11/5/2015Q315($0.12)($0.19)$18.89 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.10)($0.19)$12.77 million$1.10 millionViewListenView Earnings Details
5/6/2015Q115($0.14)($0.16)$9.84 million$2.73 millionViewListenView Earnings Details
3/12/2015Q414($0.18)($0.27)$2.48 million$17.80 millionViewListenView Earnings Details
10/29/2014Q3$0.03$0.03$21.52 million$39.53 millionViewListenView Earnings Details
8/4/2014Q2($0.12)($0.19)$11.79 million$1.34 millionViewListenView Earnings Details
4/29/2014Q114($0.20)($0.20)$1.10 million$1.40 millionViewN/AView Earnings Details
3/4/2014Q4($0.16)$0.08$1.26 million$32.90 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.20)($0.20)$1.00 millionViewListenView Earnings Details
11/1/2012Q312($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CTI BioPharma Corp. (NASDAQ:CTIC)
Current Year EPS Consensus Estimate: $-2.40 EPS
Next Year EPS Consensus Estimate: $-2.40 EPS

Dividends

Dividend History for CTI BioPharma Corp. (NASDAQ:CTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CTI BioPharma Corp. (NASDAQ:CTIC)
Insider Ownership Percentage: 8.08%
Institutional Ownership Percentage: 15.45%
Insider Trades by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)
Institutional Ownership by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)
Insider Trades by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/24/2016James A BiancoCEOSell10,000$0.37$3,700.00View SEC Filing  
5/27/2016James A BiancoCEOSell10,000$0.45$4,500.00View SEC Filing  
4/29/2016James A BiancoCEOSell10,000$0.52$5,200.00View SEC Filing  
3/28/2016James A BiancoCEOSell10,000$0.49$4,900.00View SEC Filing  
3/21/2016James A BiancoCEOSell318,169$0.55$174,992.95View SEC Filing  
3/4/2016Matthew PlunkettEVPSell10,000$0.59$5,900.00View SEC Filing  
2/26/2016Jack W SingerEVPSell15,000$0.63$9,450.00View SEC Filing  
2/26/2016James A BiancoCEOSell10,000$0.63$6,300.00View SEC Filing  
2/16/2016James A BiancoCEOSell100,000$0.42$42,000.00View SEC Filing  
2/4/2016Matthew PlunkettEVPSell10,000$1.15$11,500.00View SEC Filing  
1/29/2016Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
1/29/2016James A BiancoCEOSell10,000$1.20$12,000.00View SEC Filing  
1/8/2016Value Fund L P BiotechnologyInsiderBuy1,001,327$1.22$1,221,618.94View SEC Filing  
1/4/2016Matthew PlunkettEVPSell10,000$1.21$12,100.00View SEC Filing  
12/30/2015James A. BiancoCEOSell110,000$1.26$138,600.00View SEC Filing  
12/28/2015James A. BiancoCEOSell10,000$1.29$12,900.00View SEC Filing  
12/18/2015Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
12/4/2015Matthew PlunkettEVPSell10,000$1.00$10,000.00View SEC Filing  
11/27/2015Jack W. SingerEVPSell15,000$1.21$18,150.00View SEC Filing  
11/27/2015James A BiancoCEOSell10,000$1.23$12,300.00View SEC Filing  
11/19/2015Louis A. BiancoEVPSell15,000$1.13$16,950.00View SEC Filing  
10/30/2015James A BiancoCEOSell260,000$1.35$351,000.00View SEC Filing  
10/29/2015Louis A. BiancoEVPSell10,000$1.41$14,100.00View SEC Filing  
10/23/2015Jack W. SingerEVPSell15,000$1.62$24,300.00View SEC Filing  
10/22/2015Louis A BiancoEVPSell10,000$1.58$15,800.00View SEC Filing  
10/5/2015Matthew PlunkettEVPSell10,000$1.52$15,200.00View SEC Filing  
9/30/2015Jack W. SingerEVPSell100,000$1.42$142,000.00View SEC Filing  
9/30/2015James A. BiancoCEOSell600,000$1.43$858,000.00View SEC Filing  
9/30/2015Richard L. LoveDirectorSell13,660$1.45$19,807.00View SEC Filing  
9/29/2015Louis A. BiancoEVPSell170,000$1.41$239,700.00View SEC Filing  
9/25/2015Jack W. SingerEVPSell15,000$1.64$24,600.00View SEC Filing  
9/24/2015Matthew PlunkettEVPSell75,869$1.57$119,114.33View SEC Filing  
9/4/2015Matthew PlunkettEVPSell10,000$1.54$15,400.00View SEC Filing  
8/28/2015Jack W. SingerEVPSell15,000$1.58$23,700.00View SEC Filing  
7/24/2015Jack W SingerEVPSell15,000$1.91$28,650.00View SEC Filing  
7/23/2015Louis A BiancoEVPSell10,000$1.91$19,100.00View SEC Filing  
7/6/2015Matthew PlunkettEVPSell10,000$1.95$19,500.00View SEC Filing  
6/26/2015Jack W SingerEVPSell15,000$2.07$31,050.00View SEC Filing  
6/25/2015Louis A BiancoEVPSell10,000$2.18$21,800.00View SEC Filing  
6/4/2015Matthew PlunkettEVPSell10,000$2.06$20,600.00View SEC Filing  
5/22/2015Jack W SingerEVPSell15,000$1.74$26,100.00View SEC Filing  
5/21/2015Louis A BiancoEVPSell10,000$1.80$18,000.00View SEC Filing  
5/4/2015Matthew PlunkettEVPSell10,000$1.86$18,600.00View SEC Filing  
4/24/2015Jack W SingerEVPSell15,000$1.96$29,400.00View SEC Filing  
4/23/2015Louis A BiancoEVPSell10,000$1.93$19,300.00View SEC Filing  
4/6/2015Matthew PlunkettEVPSell16,569$1.88$31,149.72View SEC Filing  
3/23/2015James A BiancoCEOSell175,199$1.95$341,638.05View SEC Filing  
3/23/2015Matthew PlunkettEVPSell59,130$1.96$115,894.80View SEC Filing  
3/20/2015Louis A BiancoEVPSell63,000$1.94$122,220.00View SEC Filing  
2/27/2015Jack W SingerEVPSell15,000$2.35$35,250.00View SEC Filing  
2/5/2015Louis A BiancoEVPSell10,000$2.22$22,200.00View SEC Filing  
2/4/2015Matthew PlunkettEVPSell12,000$2.22$26,640.00View SEC Filing  
1/8/2015Louis A BiancoEVPSell10,000$2.32$23,200.00View SEC Filing  
1/5/2015Matthew PlunkettEVPSell12,000$2.36$28,320.00View SEC Filing  
12/19/2014James A BiancoCEOSell40,000$2.44$97,600.00View SEC Filing  
12/4/2014Louis A BiancoEVPSell10,000$2.25$22,500.00View SEC Filing  
11/6/2014Louis A BiancoEVPSell10,000$2.37$23,700.00View SEC Filing  
10/6/2014Matthew PlunkettEVPSell12,000$2.39$28,680.00View SEC Filing  
9/23/2014Matthew PlunkettEVPSell103,635$2.56$265,305.60View SEC Filing  
9/22/2014James A BiancoCEOSell307,068$2.53$776,882.04View SEC Filing  
9/22/2014Matthew PlunkettEVPSell51,817$2.58$133,687.86View SEC Filing  
9/19/2014Louis A BiancoEVPSell145,000$2.59$375,550.00View SEC Filing  
9/4/2014Matthew PlunkettEVPSell27,301$2.48$67,706.48View SEC Filing  
8/15/2014James A BiancoCEOSell40,000$2.54$101,600.00View SEC Filing  
8/4/2014Matthew PlunkettEVPSell12,000$2.48$29,760.00View SEC Filing  
7/10/2014Louis A BiancoEVPSell10,000$2.73$27,300.00View SEC Filing  
7/7/2014Matthew PlunkettEVPSell12,000$2.89$34,680.00View SEC Filing  
6/27/2014James A BiancoCEOSell50,000$2.84$142,000.00View SEC Filing  
6/5/2014Louis A BiancoEVPSell10,000$2.97$29,700.00View SEC Filing  
5/1/2014Louis BiancoEVPSell10,000$2.91$29,100.00View SEC Filing  
3/28/2014Vartan GregorianDirectorSell82,000$3.41$279,620.00View SEC Filing  
3/25/2014Phillip Phd NudelmanDirectorSell100,000$3.56$356,000.00View SEC Filing  
3/24/2014Jack SingerEVPSell60,000$3.47$208,200.00View SEC Filing  
3/21/2014James BiancoCEOSell395,000$3.83$1,512,850.00View SEC Filing  
3/21/2014Matthew PlunkettEVPSell170,000$3.73$634,100.00View SEC Filing  
3/7/2014Fred TellingDirectorSell72,095$3.75$270,356.25View SEC Filing  
9/23/2013James A BiancoCEOSell130,551$1.50$195,826.50View SEC Filing  
8/30/2013James A BiancoCEOSell25,925$1.08$27,999.00View SEC Filing  
8/9/2013James A BiancoCEOSell40,000$1.07$42,800.00View SEC Filing  
8/7/2013Mary Oneil MundingerDirectorSell125,000$1.06$132,500.00View SEC Filing  
8/6/2013Phillip M Phd NudelmanDirectorSell50,000$1.09$54,500.00View SEC Filing  
7/26/2013James A BiancoCEOSell25,688$1.09$27,999.92View SEC Filing  
6/28/2013James A BiancoCEOSell26,053$1.08$28,137.24View SEC Filing  
6/5/2013Jack W SingerEVPSell10,000$1.26$12,600.00View SEC Filing  
5/31/2013James A BiancoCEOSell28,000$1.22$34,160.00View SEC Filing  
5/31/2013Louis A BiancoEVPSell33,712$1.24$41,802.88View SEC Filing  
5/30/2013Fred TellingDirectorSell64,798$1.24$80,349.52View SEC Filing  
5/24/2013Richard L LoveDirectorSell23,000$1.21$27,830.00View SEC Filing  
5/10/2013James A BiancoCEOSell25,000$1.16$29,000.00View SEC Filing  
5/9/2013Louis A BiancoEVPSell50,000$1.15$57,500.00View SEC Filing  
3/11/2013Jack W SingerEVPSell13,000$1.28$16,640.00View SEC Filing  
8/10/2012James A BiancoCEOSell10,000$0.42$4,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CTI BioPharma Corp. (NASDAQ:CTIC)
Latest Headlines for CTI BioPharma Corp. (NASDAQ:CTIC)
Source:
DateHeadline
benzinga.com logo20 Stocks Moving In Friday's Pre-Market Session | Benzinga - Benzinga
www.benzinga.com - August 18 at 10:46 PM
seekingalpha.com logoCTI Biopharma's Pacritinib: Where We Stand Today - Seeking Alpha
seekingalpha.com - August 14 at 6:00 PM
seekingalpha.com logoCTI BioPharma's (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 5:54 PM
seekingalpha.com logoCTI BioPharma's (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 5:54 PM
finance.yahoo.com logoEdited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:54 PM
finance.yahoo.com logoEdited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:54 PM
americanbankingnews.com logoCTI BioPharma Corp. (NASDAQ:CTIC) Releases Earnings Results, Beats Estimates By $0.63 EPS
www.americanbankingnews.com - August 3 at 7:02 PM
rttnews.com logoEARNINGS SUMMARY: Details of CTI BioPharma Corp. Q2 Earnings Report
www.rttnews.com - August 3 at 7:01 PM
finance.yahoo.com logoInvestor Network: CTI BioPharma Corp. to Host Earnings Call
finance.yahoo.com - August 3 at 7:01 PM
finance.yahoo.com logoCTI BioPharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 7:01 PM
finance.yahoo.com logoCTI BioPharma posts 2Q profit
finance.yahoo.com - August 3 at 7:01 PM
benzinga.com logoCTI BioPharma Announces First Patient Enrolled in...
www.benzinga.com - August 2 at 11:32 PM
streetinsider.com logoCTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of Pacritinib
www.streetinsider.com - August 2 at 11:32 PM
prnewswire.com logoCTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who ... - PR Newswire (press release)
www.prnewswire.com - August 2 at 6:29 PM
finance.yahoo.com logoCTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma
finance.yahoo.com - August 2 at 4:18 AM
streetinsider.com logoCTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of Pacritinib - StreetInsider.com
www.streetinsider.com - August 1 at 11:17 PM
finance.yahoo.com logoCTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
finance.yahoo.com - August 1 at 3:34 AM
finance.yahoo.com logoCTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017
finance.yahoo.com - July 27 at 2:28 AM
prnewswire.com logoCTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, MD, to Board of Directors - PR Newswire (press release)
www.prnewswire.com - July 25 at 5:35 PM
streetinsider.com logoCTI BioPharma (CTIC) Appoints Veteran Laurent Fischer, MD, to Board of Directors - StreetInsider.com
www.streetinsider.com - July 24 at 10:59 AM
finance.yahoo.com logoCTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
finance.yahoo.com - July 24 at 10:59 AM
baystreet.ca logoCTI BioPharma Gains European Medicines Nod - Baystreet.ca
www.baystreet.ca - July 15 at 1:28 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: July 14, 2017
seekingalpha.com - July 14 at 8:27 PM
nasdaq.com logoFDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue ... - Nasdaq
www.nasdaq.com - July 14 at 3:26 PM
streetinsider.com logoCTI BioPharma (CTIC) Announces EMA Validation of Pacritinib MAA ... - StreetInsider.com
www.streetinsider.com - July 14 at 3:26 PM
rttnews.com logoFDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue Grows 33%
www.rttnews.com - July 14 at 4:56 AM
prnewswire.com logoCTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application ... - PR Newswire (press release)
www.prnewswire.com - July 13 at 6:47 PM
finance.yahoo.com logoCTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia
finance.yahoo.com - July 13 at 6:47 PM
americanbankingnews.com logo Analysts Expect CTI BioPharma Corp. (CTIC) to Announce -$0.70 Earnings Per Share
www.americanbankingnews.com - July 5 at 12:22 AM
americanbankingnews.com logoShort Interest in CTI BioPharma Corp. (CTIC) Decreases By 50.0%
www.americanbankingnews.com - June 30 at 7:14 AM
seekingalpha.com logoPremarket Gainers as of 9:05 am - Seeking Alpha
seekingalpha.com - June 15 at 11:28 PM
prnewswire.com logoCTI BioPharma Receives $10 Million Milestone Payment for ... - PR Newswire (press release)
www.prnewswire.com - June 15 at 11:28 PM
streetinsider.com logoPre-Open Movers 06/15: (HTGM) (CTIC) (YTRA) Higher; (KR) (ARNA) (GOOGL) Lower (more...)
www.streetinsider.com - June 15 at 6:28 PM
baystreet.ca logoCTI Hikes on Teva Milestone Payment
www.baystreet.ca - June 15 at 6:28 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-CTi BioPharma, Epizyme, Western Digital
www.nasdaq.com - June 15 at 6:28 PM
finance.yahoo.com logoCTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
finance.yahoo.com - June 15 at 3:33 AM
americanbankingnews.com logoCTI BioPharma Corp (CTIC) Expected to Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - June 8 at 10:16 PM
finance.yahoo.com logoETFs with exposure to CTI BioPharma Corp. : June 8, 2017
finance.yahoo.com - June 8 at 5:34 PM
streetinsider.com logoCTI BioPharma (CTIC) Announces Public Offering Of Convertible Preferred Stock - StreetInsider.com
www.streetinsider.com - June 7 at 4:47 PM
finance.yahoo.com logoCTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock
finance.yahoo.com - June 6 at 4:49 PM
streetinsider.com logoCTI BioPharma (CTIC) Announces Public Offering Of Convertible Preferred Stock
www.streetinsider.com - June 6 at 2:36 AM
finance.yahoo.com logoCTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations
finance.yahoo.com - June 5 at 4:35 PM
finance.yahoo.com logoCTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock
finance.yahoo.com - June 5 at 4:35 PM
finance.yahoo.com logoETFs with exposure to CTI BioPharma Corp. : May 25, 2017
finance.yahoo.com - May 25 at 6:14 PM
americanbankingnews.com logo Analysts Anticipate CTI BioPharma Corp (CTIC) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - May 12 at 8:30 PM
finance.yahoo.com logoETFs with exposure to CTI BioPharma Corp. : May 8, 2017
finance.yahoo.com - May 8 at 9:26 PM
finance.yahoo.com logoCTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 4:48 PM
rttnews.com logoEARNINGS SUMMARY: Details of CTI BioPharma Corp. Q1 Earnings Report
www.rttnews.com - May 5 at 2:44 AM
americanbankingnews.com logoCTI BioPharma Corp (CTIC) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 4 at 9:02 PM
finance.yahoo.com logoCTI BioPharma reports 1Q loss - Yahoo Finance
finance.yahoo.com - May 4 at 7:09 AM

Social

Chart

CTI BioPharma Corp. (CTIC) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by MarketBeat.com Staff